Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma

Journal of Immunotherapy

Volumn 26, Issue 5, 2003, Pages 385-393

  Rosenberg, Steven A ^a   Yang, James C ^a   Robbins, Paul F ^a   Wunderlich, John R ^b   Hwu, Patrick ^b   Sherry, Richard M ^b   Schwartzentruber, Douglas J ^c   Topalian, Suzanne L ^c   Restifo, Nicholas P ^c   Filie, Armando ^c   Chang, Richard ^c   Dudley, Mark E ^c  

^a Center for Cancer Research   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cancer; Immunotherapy; Melanoma

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ADULT; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE REPORT; CELL TRANSFER; FEMALE; GENE EXPRESSION; HUMAN; IMMUNE STATUS; IMMUNOREACTIVITY; INTRAARTERIAL DRUG ADMINISTRATION; LYMPHOCYTE; MELANOMA; METASTASIS; PRIORITY JOURNAL; TUMOR REGRESSION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 10744223842     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200309000-00001     Document Type: Article

References (17)

1. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst. 1994; 86:1159-1166.
2. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients following clonal repopulation with anti-tumor lymphocytes. Science. 2002; 298:850-854.
3. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA. 1994; 271:907-913.
4. Dudley ME, Ngo LT, Westwood J, et al. T cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J Sci Am. 2000; 6:69-77.
5. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunotherapy. 2001; 24:363-373.
6. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995; 333:1038-1044.
7. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Meth. 1990; 128:189-201.
8. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998; 4:321-327.
9. Dudley M, Wunderlich J, Yang JC, et al. A phase I study of non-myeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002; 25:243-251.
10. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. PNAS. 2002:1-6.
11. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplation. N Engl J Med. 2000; 343:750-758.
12. Dudley M. Cell transfer therapy: Basic principles and preclinical studies. In:Principles and Practice of the Biological Therapy of Cancer, 3rd ed. 2000;305-321.
13. Marroquin CE, White DE, Steinberg SM, et al. Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer. J Immunother. 2000; 23:387-392.
14. Kish JA, Kopecky K, Samson MK, et al. Evaluation of fludarabine phosphate in malignant melanoma. Southwest Oncology Group study. Invest New Drugs. 1991; 9:105-108.
15. Pockaj BA, Sherry R, Wei J, et al. Localization of Indium-lll-labelled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: augmentation with cyclophosphamide in association with response. Cancer. 1994; 73:1731-1737.
16. Restifo NP, Marincola FM, Kawakami Y, et al. Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996; 88:100-108.
17. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol. 2002; 3:999-1005.